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1. Introduction 
Uterine contractions occur in runs of 1-3/hr throughout pregnancy from early in the second 
trimester until full term usually without consequence. Regular uterine contractions are 
essential in every case of preterm labor (PTL) resulting in preterm delivery at <37 weeks. It 
has been demonstrated that women are unable to accurately perceive the contractions 
associated with preterm labor while uterine contraction monitoring can frequently detect 
these contractions at an early enough time that acute tocolysis can stop preterm labor in 
most cases and significantly prolong the pregnancy. In women who have cervical 
shortening, those who have preterm labor symptomatology with multifetal gestations, or 
patients who have already had an episode of preterm labor, uterine contraction monitoring 
has been helpful in prolonging the pregnancy by early detection. As an example, women, 
after receiving tocolysis for true preterm labor, are monitored (tertiary prevention) in the 
home (whether or not they are receiving maintenance tocolytics) and when a second episode 
of PTL occurs, the majority reach the hospital for appropriate treatment before excessive 
cervical dilatation has occurred. Alternatively, following successful acute tocolysis in the 
hospital, patients may receive maintenance tocolysis with a subcutaneous terbutaline 
infusion pump and are also managed at home with continued contraction assessment. This 
chapter will review the available literature regarding the use of contraction monitoring for 
tertiary prevention as well as subcutaneous terbutaline maintenance therapy for treatment 
of contractions.  
2. Background 
2.1 General 
The incidence of preterm birth (PTB), or delivery at <37 weeks, continues to increase and 
accounts for 75% of all neonatal mortality and morbidity.(Hamilton et al., 2006) All 
physicians agree that preterm delivery (PTD) following preterm labor (PTL) involves 
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frequent uterine contractions which dilate the cervix. In fact, the definition of preterm 
labor involves uterine contractions <5 minutes apart and cervical change (usually >1cm 
dilatation or cervical shortening (or thinning) by ultrasound). Contractions that do not 
meet that frequency or contractions without cervical change several hours after uterine 
activity starts are called uterine irritability, irregular contractions, Braxton Hicks 
contractions, or false labor, but have no effect on the cervix are never called preterm 
labor. In order to delay or prevent PTD, true uterine contractions should be detected 
sufficiently early (cervical dilatation <4 cm), to allow reasonable success of tocolytic drugs 
to result in meaningful pregnancy prolongation.(ACOG Practice Bulletin, 2007) 
Unfortunately, painful, irregular uterine contractions can also be associated with false 
labor or uterine irritability and even when they are strong, much less than 50% are 
perceived by patients.(Beckmann et al., 1996; Faustin et al., 1997) PTL can be acute 
(abruptly going from normal contraction frequency of 1-2/hr on average to >8 ctx/hr) or 
gradual (over days). Basal uterine activity is important clinically, since the goal is to detect 
an increase in contractions in a timely fashion. 
2.2 Uterine contraction monitoring  
The detection of contractions in asymptomatic patients to rule out true preterm labor for 
some identified risk factor by uterine activity assessment or palpation alone has meet with 
variable success.(Faustin et al., 1997; Martin et al., 1990; Dyson et al., 1998) The use of 
uterine contraction monitoring and patient recorded signs and symptoms is more 
successful (secondary prevention) but does not yield high enough positive predictive 
value to be useful as a assessment tool for those with high risk factors.(Dyson et al., 1998) 
Some patients are at extremely high risk for preterm delivery such as those who have 
already experienced an episode of true preterm labor with cervical dilatation or women 
with multi-fetal gestations (MFG), or those with a significantly shortened cervix. These 
patients have all been shown to benefit from uterine activity monitoring (tertiary 
prevention).(Morrison et al., 2001; Katz et al., 1986; Watson et al., 1990; Kosasa et al., 1990) 
Contraction assessment is particularly important in MFG as the contraction pattern is 
different from that in singletons. Newman et al., (1986) demonstrated that twins have 
statistically more contractions/hr than singletons averaging 2/hr at 29 weeks, 3/h at 33 
weeks, and 4/h at 36 weeks. Garite et al., (1990) demonstrated a crescendo of contractions 
in twins, triplets and quads starting approximately 48 hrs prior to PTL (3.5 ctx/hr + 1.4) 
and at 24 hrs prior to PTL (5.3 ctx / hr + 1.3) Hernandez et al., (2008) demonstrated that 
twins who developed PTL with or without early delivery had significantly more baseline 
contractions compared to twins who never developed PTL. Contractions exceeded 3.5/hr 
at 29-1/2 weeks in those developing PTL. Newman et al., (2006) could not identify a 
threshold number of uterine contractions that would predict PTL but confirmed that 
twins have more UC at each gestational age (GA) than singletons and that UC increase 
with advancing GA and also time of day (1600-0359 hours). Rust et al., (1997) compared 
twins who developed PTL <24 weeks. In this study, 31 patients had been placed on 
contraction monitoring prior to PTL and 32 were prescribed home contraction monitoring 
after PTL was arrested. The GA at diagnosis of PTL was similar, but cervical dilation was 
significantly different, with the twins already on a monitor being less dilated (1.1 + 0.5 cm 
vs 2.3 + 0.8 cm p .0001). The twin pregnancies already undergoing contraction monitoring 
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delivered at a mean GA 34.7+ 2.8 wks compared to 27.6 + 2.5 wks for those placed on 
monitoring after PTL was arrested at <24 wks (p < .001). 
2.3 Higher order multiples  
Triplets and quadruplets are referred to as high order multiple (HOM) pregnancies. Preterm 
labor is confirmed in 80% of triplet pregnancies and 98% of quads, occurs at an earlier 
gestational age, and the mothers are almost always unaware of the contractions due to 
increased fetal movement.(Elliott et al., 1995) Elliott et al., (1995) utilized HUAM to 
determine a weekly average of contractions/hour for patients with HOM gestation. With 
two, one-hour monitoring sessions per day the total number of observed contractions were 
divided by 14 and utilized as an average number (eg 3.9 ctx /hr) that week. In support, 
Garite et al., (1990) reported that patients with singleton pregnancies increased their 
contractions to 3.5/hr 48 hours prior to PTL developing, while (Elliott et al., 1995) found that 
HOM gestations who were given betamethasone developed increasing contractions and true 
PTL/delivery statistically more frequently if the baseline number of UC was greater than 
3.5/hr compared to those with a baseline contraction frequency that was less than 3.5/hr. 
Based on this arbitrary number of contractions/hr (3.5 UC/hr) (Elliott et al., 1997) started 
tocolysis prophylactically, utilizing terbutaline pump therapy to attempt to prevent PTL that 
can result in PTD. The results of this report showed that in 15 sets of triplets and 6 sets of 
quads only 14% delivered due to PTL; much less than the reported incidence in other series. 
This underscores the importance of determining uterine contraction frequency and then 
potentially initiating preventative therapy. Therefore, the rationale of using contraction 
monitoring for tertiary prevention as well as treatment using subcutaneous terbutaline is 
supported by various studies but what are the clinical results of such investigations?  
2.4 Contraction monitoring with maintenance tocolysis 
In general, tertiary assessment results in an earlier diagnosis of recurrent preterm labor at 
less cervical dilatation, which improves the success of tocolysis and results in greater 
pregnancy prolongation when compared with standard care even when both groups used 
maintenance tocolysis.(Morrison et al., 2001; Katz et al., 1986; Watson et al., 1990; Kosasa et 
al., 1990; Smith et al., 1994) Furthermore, after tocolysis of the second PTL episode or in 
pregnancies with advanced cervical dilation (>3-4cm), the combination of continued uterine 
contraction monitoring along with subcutaneous terbutaline infusion using a programmable 
pump have resulted in significantly prolonged gestation compared to no treatment or oral 
maintenance therapy.(Elliott et al., 2001; Morrison et al., 2003; Lam et al., 2001) Both 
contraction monitoring and terbutaline administration by subcutaneous pump, when used 
in appropriate patients, significantly increased the length of pregnancy, resulted in fewer 
low birth weight infants, and reduced neonatal stay as well as neonatal cost.(Martin et al., 
1990; Smith et al., 1994; Morrison et al., 2003; Lam et al., 2001) 
2.5 Purpose 
The purpose of this chapter is to review the literature regarding uterine contraction 
monitoring, when used for tertiary prevention, and to assess studies using subcutaneous 
terbutaline infusion (when employed in conjunction with uterine contraction monitoring) in 
women who had previously had an episode of confirmed preterm labor, and those with 
twins or higher order multiples demonstrating cervical change.  
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3. Tertiary uterine contraction monitoring 
3.1 Method of contraction monitoring 
Regarding contraction monitoring for tertiary prevention, only randomized clinical trials 
(RCT) or cohort studies with appropriate matched controls were considered. A review of the 
literature revealed seven acceptable trials from 1985 to 2005, using uterine contraction 
monitoring for tertiary care. There were three additional studies that were eliminated 
because the HUAM group was not compared to a standard of care control group or because 
women with current preterm labor as a subgroup were never reported separately. Women 
using contraction assessment in the home monitored uterine activity for two hours per day 
(usually once in the morning and once in the afternoon) using a sensitive guard-ring 
principal monitoring. On a daily basis a nurse initiated a phone call and transmitted the two 
hours of monitoring to assess the number and quality of the contractions present. During 
this daily phone call the nurse asked about symptoms of preterm labor, such as pelvic 
heaviness, uterine contractions, tightening increase in cervical discharge, etc. If signs and 
symptoms of preterm labor where present or if there were >4 contractions per hour, the 
patient was asked to hydrate and re-monitor. If these repeat data were not satisfactory, the 
patient was sent to the hospital. In addition, during the daily phone call, the education 
regarding signs or symptoms of PTL and patient’s specific educational objectives were 
reinforced. Finally, these women had access to a 24/7 availability toll free calls to a nurse 
other than the person who made the daily phone call. All women attended a special preterm 
birth prevention clinic, where cervical assessment digitally or by ultrasound was carried out 
along with an assessment of preterm labor signs and symptoms and other testing such as, 
cultures, fetal fibronectin, and a variety of educational techniques at the discretion of the 
physician. Women in the various cohort or control groups frequently attended the same 
clinics with the same education, but were taught palpation for uterine activity, which they 
recorded daily. 
3.2 Results of tertiary contraction monitoring 
As shown in Table I, the study by Katz revealed an average of 68% reduction in preterm 
birth when patients using uterine contraction monitoring in the home were compared to the 
standard care control group.(Katz et al., 1986) In the prospective controlled study by Kosasa, 
preterm delivery rates were not reported, but in women prescribed contraction monitoring 
after preterm labor was arrested, there was a pregnancy prolongation of 4.6 weeks and an 
average gestational age of delivery at 36.7 weeks.(Kosasa et al., 1990) In addition, there 
was a cost savings of $21,200.00 in the contraction monitoring group versus the standard 
care group for such high risk patients. Katz et al., (1988) studied 120 women after an 
episode of confirmed preterm labor. Half of the patients received contraction monitoring 
compared to self-palpation. Preterm births among monitored patients were significantly 
less than the control group (15 versus 34%, p<.05) and more importantly time gained in 
utero was 7.4 + 3.0 weeks in the monitored group versus 4.0 + 1.2 weeks in controls.(Katz 
et al., 1988) Morrison et al., (2001) found similar results in a Medicaid population where 
pregnancy prolongation was extended, there were fewer preterm births, and the cost 
saving was significantly more ($14,459.00) among monitored patients when compared to 
controls. Morrison et al., (2001) Watson et al., (1990) in a randomized clinical trial among 
women discharged on monitoring versus control patients, found that there were 44% 
fewer preterm births compared to control women (p<.05) with a higher incidence of failed 
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tocolysis also among control women resulting in a longer mean time gained in utero for 
monitored women.  
 
 
Table 1. Utilization of huam for tertiary care evidence table. 
Nagey et al., (1993) studied 28 women who were discharged from the hospital after tocolysis 
and received HUAM versus 29 women who received routine care. Since there was no daily 
perinatal contact or 24/7 availability of calling the nurse, there was considerably more non-
compliance (26/28) in the monitored group and accordingly there was no difference in 
pregnancy prolongation or preterm deliveries. Additionally, 4 patients out of the 28 in the 
monitoring group were never discharged and did not receive monitoring at all. Finally, the 
authors did not meet their power calculation, as 45 in each group were needed to show a 
detectable difference for contraction monitoring. Pregnancy prolongation and neonatal 
morbidity statistics were not reported in this study. Smith et al., (1994) studied women 
discharged after preterm labor using contraction monitoring versus a like number who 
served as matched controls. Among monitoring women, pregnancy prolongation, 
gestational age at birth, and number delivering <37 weeks compared to control patients 
were significantly improved (p<.011). Brown et al., (1999) studied 86 women who were 
assigned to monitoring compared to 80 in an unmonitored group following effective acute 
tocolysis. Unfortunately, the number needed to show a significant difference in preterm 
delivery was 438 and only 162 were enrolled over a 7-year period. Therefore, no differences 
in preterm delivery or pregnancy prolongation were noted but since daily contact with a 
nurse was allowed, the number of NICU admissions was reduced in both groups (24%, 27%) 
compared to other studies. 
3.3 Contraction monitoring: Pooled results 
When these studies are pooled, the preterm delivery rate (<37 weeks) in the monitored 
group was 30.6% versus 48.9% among control patients. In the 2 studies reporting data for 
<35 week deliveries, the monitored group was favored (7.7% versus 22.9%).(Morrison et al., 
2001; Brown et al., 1999) This translated into a pregnancy prolongation of 7.8 weeks in the 
monitored group versus 4.4 weeks in the control group. Two studies reported NICU rates of 
admission (Smith et al., 1994; Brown et al., 1999) and the pooled data reveals a 7.2% NICU 
admission rate for monitored patients versus 36.2% among the infants of control women. 
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Pregnancy prolongation resulted in a total cost savings amongst the studies who collected 
financial data (Morrison et al., 2001; Kosasa et al., 1990) of $413,153 or $13,153/per pregnancy 
compared to control group women. Among secondary prevention studies including patients 
who had preterm labor in the current gestation, Floyd and Morrison also revealed benefit 
for these monitored patients versus control subjects with respect to pregnancy prolongation 
and preterm deliveries.(Floyd et al., 1993; Morrison et al., 1990) In sum, when patients use 
contraction monitoring for tertiary care (after discharge from an episode of acute preterm 
labor in the current pregnancy), there is a significant prolongation of pregnancy and fewer 
preterm deliveries, which results in fewer NICU admissions and less neonatal morbidity as 
well as cost among monitored patients compared to controls.  
4. Maintenance tocolysis 
4.1 Tocolytic choices 
The data presented in Table I supports monitoring contractions, particularly to detect 
recurrent preterm labor after successful treatment of the initial episode of early labor. The 
therapeutic strategies for such women, however is disparate. Although there is not reliable 
data because such women are rarely studied, a large number of patients each year who have 
been successfully treated for preterm labor remain in the hospital until delivery, rather than 
being sent home. To be sure this appropriately includes some patients with advanced 
cervical dilatation (>4cm), others with concominant medical/obstetric problems or women 
who have geographic difficulties with transportation or patients who are considered to be 
unreliable. In our clinical experience however, these are the minority and most women 
remaining in hospital simply do so to reduce medical/legal risks or assuage 
maternal/physician anxiety. Clearly this is not cost or health effective. Many of these 
patients would qualify for discharge and monitoring with terbutaline subcutaneous therapy 
or oral tocolytic treatment in the home. Secondly, many physicians do not prescribe tocolytic 
maintenance therapy to women who are sent home because studies have shown that oral 
therapy does not extend pregnancy compare to placebo.(Rust et al., 1996) Calcium channel 
blockers such as nifedipine are also utilized for maintenance tocolysis. There have been two 
placebo controlled trials with nifedipine and neither have shown any difference in 
gestational age at delivery, time gained in utero, deliveries at term, or composite neonatal 
morbidity when compared to placebo patients.(Carr et al., 1999; Lyell et al., 2008) In addition, 
maternal myocardial infarction, hepatic toxicity, and hypotension with fetal distress, as well 
as a reduction in uterine artery pulsatility index with fetal death have all been reported with 
the oral use of nifedipine for preterm labor particularly when the dose is increased.(Abbasi 
et al., 2003; van Geijn et al., 2005) Therefore, the choice of oral nifedipine for maintenance 
tocolysis, similar to oral terbutaline or oral magnesium, does not appear to be solid as its 
efficacy is questionable and there are significant maternal and fetal side effects. Regardless, 
women who are discharged after acute preterm labor is stopped, need uterine contraction 
monitoring whether they use oral tocolytics, the terbutaline pump, or no medication. 
4.2 Do oral tocolytics work  
It is clear that many patients in the treatment arm of these studies whether it be, oral 
terbutaline, oral magnesium or nifedipine simply did not receive an adequate dose of the 
drug due to maternal side effects. For example, there are several studies which show that 
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when maintenance tocolysis is discontinued, between 30% and 50% of patients deliver 
within 24 to 72 hours.(Jones et al., 2006; Rebarber et al., 2009) Teleologically, it seems unlikely 
that patients who have been on tocolysis for several weeks or months would deliver within 
1-3 days (and 70-80% within 1 week) if the tocolytic agent did not cause cessation of uterine 
contractions. Therefore, it may not be that oral tocolytics don’t work when given in a 
maintenance form, it may just be, that the effective dosage of medications have side effects 
resulting in poor compliance or discontinuation of treatment. In summary, the issue of 
maintenance tocolysis is not clear-cut. While it is not cogent to leave all patients in the hospital 
after an episode of acute preterm labor, if one is not going to use maintenance tocolysis on an 
ambulatory basis, at the very least, home contraction monitoring with daily nursing calls 
should be utilized in our opinion to detect recurrent preterm labor at the earliest time.  
5. Subcutaneous terbutaline pump usage 
5.1 Requirements for terbutaline pump 
Another area in which contraction monitoring is essential is during maintenance tocolysis 
therapy employing a subcutaneous terbutaline infusion pump. When the subcutaneous 
terbutaline pump was used versus or maintenance drugs (or no oral tocolysis) 46 peer 
review studies were noted. In each study involving the terbutaline pump, it was required 
that uterine contraction monitoring was utilized since this end organ response (uterine 
contraction) was necessary to guide bolus terbutaline dosing. Additionally, it was required 
that such investigations utilize pharmacy consultation to calculate the volume of 
distribution in order to give an appropriate basal dose of terbutaline parenterally. Daily 
nursing contact (usually by phone) was carried out to detect patient reported signs and 
symptoms as well as two, one hour monitoring periods (usually one in the morning and one 
in the evening). Of all the terbutaline studies, there were three randomized clinical trials 
(Level I), 26 observational case control/cohort studies (Level II), and 17 descriptive case 
series (Level III). Two studies (Wenstrom et al., 1997; Guinn et al., 1998) were eliminated 
because they did not allow proper usage of terbutaline treatment (pharmacy consultation to 
adjust basal dosage, contraction monitoring to adjust bolus terbutaline therapy, daily 
nursing contact, or emergency patient contact) and in addition both were vastly 
underpowered (94 enrolled, 320 required by power calculations). In the other studies, the 
outcomes of interest in both groups under study (tertiary prevention, terbutaline pump 
treatment), included pregnancy prolongation, preterm delivery rate (<37 weeks/<35 
weeks), gestational age at delivery, also NICU admission rate, as well as, the length of stay 
were noted, and if available, the cost savings per pregnancy. These were compared between 
the treatment and control group.  
In this therapy a basal rate of subcutaneous terbutaline is determined (.045-.075mg/hr) in 
consultation with a pharmacist so that the patient’s volume of distribution is calculated 
verifying that the constant level of terbutaline is optimized for that patient. Importantly, the 
basal rate is supplemented by intermittent boluses (usually .25mg terbutaline each) 
programmed by the patient during the daily nursing call timed to address increased uterine 
activity detected by contraction monitoring. These bolus doses are critical as each patient’s 
contraction pattern is different. The advantage of the small subcutaneous dosage per day, 
combining the basal rate and bolus rate (usually 2.5-3.5mg), is that there is less down 
regulation of beta-agonist receptors and a reduction in maternal side effects when compared 
to oral maintenance therapy with terbutaline (20-40mg per day). 
www.intechopen.com
 
Preterm Birth - Mother and Child 
 
208 
5.2 Results of terbutaline pump maintenance tocolysis  
As shown in Table II, the data for continuous subcutaneous terbutaline infusion is 
voluminous. There are 46 peer review publications over a 20-year period (1988-2008) 
involving over 30,000 patients. Of these 46 there are only 2 studies which did not find 
increased pregnancy prolongation, less NICU admissions and lowered cost.(Wenstrom et al., 
1997; Guinn et al., 1998) Both of these studies had critical flaws. First they were small, only 
involving 94 total patients of which 39 received the terbutaline pump, but also importantly a 
fixed basal dosage of terbutaline was used without volume of distribution calculations so 
that a 150-pound woman received the same dosage as a 350-pound woman. Also, there was 
no measurement of end organ response as contraction monitoring to determine if changes in 
bolus dosage were needed, was not allowed. Finally, neither study had enough patients  
(94 enrolled, 320 in each group required to meet a power calculation) to demonstrate 
efficacy. Of the other 44 studies, all were positive; demonstrating fewer preterm deliveries, 
greater pregnancy prolongation, less NICU admission and/or enhanced cost savings.  
 
– Lam et al, 1987
– Lam et al, 1988 
– Lam et al, 1988
– McGettigan et al, 1991
– Gianopoulos et al, 1991
– Jones et al, 1991
– Fischer et al, 1991
– Wolfsen et al, 1992
– Allbert et al, 1992
– Moise et al, 1992
– Weinbaum et al, 1992
– Elliott et al, 1992
– Lindenbaum et al, 1992
– Regenstein et al, 1993
– Adkins et al, 1993
– Allbert et al, 1994
– Perry et al, 1995
– Wenstrom et al, 1997 
– Elliott et al, 1997 
– Lam et al, 1998
– Guinn et al, 1998 
– Berkus et al, 1999
– Hamersley et al, 1999
– Lam et al, 2000
– Elliott et al, 2001
– Elliott et al, 2001
– Lam et al, 2001
– Viscarello et al, 2002
– Viscarello et al, 2002
– Elliott et al, 2002
– Hamersley et al, 2002
– Morrison et al, 2003
– Lam et al, 2003
– Fleming et al, 2004
– Ambrose et al, 2004
– Roman et  al, 2004
– Rebarber et  al, 2004
– Gaziano et  al, 2004
– Gaziano et al, 2004
– Brown et al, 2005
– Rittenberg et al, 2006
– Jones et al, 2006
– Mcweeney, 2006
– de la Torre, 2008
– Flick, 2008
– Rebarber, 2008
 
Table 2. Evidence – Continuous SQ Terbutaline. 46 Peer Review Studies 1988-2008. 
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Table III, shows the pregnancy prolongation amongst all studies where it was reported. In 
these 20 studies, pregnancy prolongation ranges from 2.4 to 11 weeks averaging 4.6 weeks 
in the treatment group. Finally, in a meta-analysis Lam et al., analyzed 6 studies with 858 
patients using subcutaneous terbutaline and contraction monitoring versus 897 patients 
who were not treated or received oral terbutaline/nifedipine.(Lam et al., 2009) It was noted 
that in the monitored group there was a 73% reduction in preterm birth <32 weeks and the 
NICU admission rate was 28.8% versus 40.7%. Overall, there was a $7,100 – $10,500 cost 
saving amongst studies who reported financial data.  
 
2.5
8.5
8
6.3
5.4
6.5
5.4
6.6
8.4
11
2.76
4.86
4.9
2.8
5.4
2.4
9.9
3.2
6.4
5.8
4.1
4.8
5.3
6.2
3.9
5
5.2
6.3
5.4
0 2 4 6 8 10 12
PO
SQ
*Elliott (2001) 104 triplets *Flick (2008 abstract) 1366 *de la Torre (2008 ) 656 twins
*Fleming (2004) 284 *Lam (2003) 558 Elliott J (2004) 9359
Morrison J (2003) 15 Viscarello R (2002) HOM Elliott J (2001) 104 Triplets
Ambrose S (2001) 90 matched *Lam F (2000) 386 Twins Elliott (1997) 6 Quads
Elliott (1997) 15 Triplets Adkins (1993) 51 Allbert (1992) 992
Moise K (1992) 13 pregnancies Gianopoulos (1991) 31 Jones (1991) 50
McGettigan (1991) 28 Lam (1988) 9 singletons
PI
Prolongation (weeks)
*=prolongation after RPTL
*= prolongation after RPTL
 
Table 3. Clinical Experience - Pregnancy Prolongation. 
6. Summary 
Following tocolysis of acute preterm labor, women discharged on maintenance therapy or 
on no tocolytic agent at all, appear to benefit from tertiary contraction assessment and daily 
nursing contact. Critical to the contraction-monitoring program, whether subcutaneous 
terbutaline is used or not, is the daily nursing assessment for signs and symptoms of 
preterm labor and monitoring of uterine activity. If the program is used correctly as 
indicated above, patients will experience a greater pregnancy prolongation resulting in 
fewer preterm births which translates into less NICU admissions and reduced neonatal 
morbidity and greater cost savings. When uterine contraction monitoring without tocolytics 
are used in these very high-risk patients the goal is to identify recurrent preterm labor at the 
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earliest possible time so that advanced cervical dilatation does not occur before tocolysis can 
be initiated. Among women using the subcutaneous terbutaline pump the goal is to 
maintain uterine quiescence by giving the appropriate basal dose (calculated on volume of 
distribution) while using uterine contraction assessment to adjust bolus therapy to extend 
the gestation as long as possible. Should recurrent preterm labor occur with either of these 
therapies, then primary or acute treatment with magnesium sulfate is indicated. Since 
several studies have noted that there is an advantage, if preterm delivery does occur, in 
treating with magnesium sulfate (decreased cerebral palsy) this should be the drug of choice 
for acute treatment of any episode of preterm labor. (Elliott et al., 2009)  
In summary, it would appear that in appropriate cases (as illustrated above) the use of 
contraction monitoring in the home is extremely helpful in early detection of recurrent 
preterm labor and extending the gestation as far as possible. This would seem to benefit the 
patient, the neonate, and society in general.  
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